Short answer
Xencor Inc (XNCR) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $21M (up 96.1% year over year) with net income of −$6M.
Q3 2025 key financials · XBRL
- Revenue
- $21M
- +96.1% YoY · −51.8% QoQ
- Net income
- −$6M
- +86.6% YoY · +80.4% QoQ
- Operating margin
- -226.3%
- EPS (diluted)
- −$0.08
- +88.4% YoY · +80.5% QoQ
Source: XBRL data from the Xencor Inc (XNCR) Q3 2025 10-Q on SEC EDGAR. USD.
Xencor Inc Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk due to ongoing U.S. government shutdown since October 1, 2025, causing FDA and SEC furloughs, delaying regulatory reviews and capital access
- Material update on regulatory risk: IRA drug price negotiations now effective, with 10 drugs priced from January 1, 2026, and 15 more selected for 2025 negotiations
- Regulatory risk intensified from legislative and legal challenges to Medicare Drug Price Negotiation Program with ongoing federal appeals
- Operational risk from supply chain disruptions and payment delays tied to global economic volatility and geopolitical trade uncertainties including tariffs involving China
- Financial risk from potential capital raising difficulties amid prolonged economic downturn and government shutdown impacting market access and FDA application timing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Xencor Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.